RNA transfection

Ethris Announces Collaboration with DIOSynVax and CEPI to Develop a Broadly Protective mRNA Vaccine Against Betacoronaviruses

Retrieved on: 
Wednesday, December 21, 2022
Science, Biotechnology, Research, Pharmaceutical, Health, COVID-19, Infectious Diseases, Clinical Trials, LNP, Partnership, Coronavirus, SARS, Biotechnology, RNA transfection, Coalition for Epidemic Preparedness Innovations, Epidemic, COVID-19, Temperature, MERS, Disease, CEPI, Therapy, Severe acute respiratory syndrome–related coronavirus, Coalition, Vaccine, RNA, Severe acute respiratory syndrome coronavirus 2, Betacoronavirus, Nobecovirus

Ethris GmbH , a leading biotechnology company pioneering next-generation messenger RNA (mRNA) therapeutics and vaccines, announced today a collaboration with UK-based DIOSynVax to jointly develop a protective mRNA vaccine candidate against a broad range of Betacoronaviruses utilizing the company’s highly differentiated mRNA modification and design technologies as well as its lipidoid nanoparticle (LNP) and stabilisation platforms.

Key Points: 
  • Ethris GmbH , a leading biotechnology company pioneering next-generation messenger RNA (mRNA) therapeutics and vaccines, announced today a collaboration with UK-based DIOSynVax to jointly develop a protective mRNA vaccine candidate against a broad range of Betacoronaviruses utilizing the company’s highly differentiated mRNA modification and design technologies as well as its lipidoid nanoparticle (LNP) and stabilisation platforms.
  • The collaboration is founded on a $42 million award to DIOSynVax by the Coalition for Epidemic Preparedness Innovations (CEPI) to support the development of a broadly protective Betacoronavirus vaccine through to a Phase I/II clinical trial.
  • Ethris will receive up to $20M to design and manufacture the mRNA vaccine candidate containing DIOSynVax’s broadly protective, multi-virus vaccine antigen payload designs.
  • The company has established its proprietary platforms to design and manufacture next-generation, well-tolerated, mRNA drug candidates with unparalleled LNP stability.

Esperovax and Ginkgo Bioworks Announce Partnership to Develop Circular RNA-based Therapeutics

Retrieved on: 
Thursday, January 5, 2023
Cancer, Partnership, RNA transfection, RNA, DNA, Death, Ginkgo, Traction, Toxicity, Colorectal cancer, Acquisition, Ginkgo Bioworks, NYSE, Medicine, Cell death, Therapy, Nobel Prize, Vaccine, Nobel Prize in Physiology or Medicine, Physiology, Plasmodium circularis

PLYMOUTH, Mich. and BOSTON, Jan. 5, 2023 /PRNewswire/ -- Esperovax, an innovative developer of oral mRNA biologics, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a partnership to develop circular RNAs (circRNAs) for a variety of therapeutic applications. Initially, Ginkgo and Esperovax will work to develop circRNAs harboring payloads to specifically target colorectal cancer by inducing cell death only in cancerous cells.

Key Points: 
  • PLYMOUTH, Mich. and BOSTON, Jan. 5, 2023 /PRNewswire/ -- Esperovax, an innovative developer of oral mRNA biologics, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a partnership to develop circular RNAs (circRNAs) for a variety of therapeutic applications.
  • Initially, Ginkgo and Esperovax will work to develop circRNAs harboring payloads to specifically target colorectal cancer by inducing cell death only in cancerous cells.
  • CircRNAs represent an emerging, powerful mechanism for delivering therapeutics and vaccines due to their protein-coding potential and improved stability in comparison to their linear mRNA counterparts.
  • This partnership aims to further exploit circRNAs by developing a novel mechanism to facilitate RNA circularization specifically in colorectal cancer cells.

Everest Medicines Announces New Strategic Plans, Reinforcing Transformation into a Fully Integrated Biopharmaceutical Company

Retrieved on: 
Tuesday, January 3, 2023
IgA nephropathy, Patient, Immunoglobulin A, Social conditions in Honduras, Partnership, RNA transfection, Growth, CMC, COVID-19, Mount Everest, HKEX, Eravacycline, Ulcerative colitis, News, Degenerative disease, Prevalence, Infection, NDA, Cancer, Vaccine, Emergency Use Authorization, Kidney, Pharmaceutical industry

SHANGHAI, Jan. 3, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced its strategic plans for the next two years and beyond as the Company progresses to becoming a fully-integrated biopharmaceutical company with expertise and capabilities across the full biotechnology value chain, including proven self-discovery and in-licensing, clinical development, and established manufacturing and commercialization . The Company's renal disease and mRNA platform portfolios, both of which comprise multiple promising early- and late-stage therapeutic candidates, will be Everest's core areas of focus.

Key Points: 
  • The Company's renal disease and mRNA platform portfolios, both of which comprise multiple promising early- and late-stage therapeutic candidates, will be Everest's core areas of focus.
  • The potential approval and launch of Nefecon, the Company's lead renal portfolio product candidate, is expected in China in the second half of 2023.
  • Everest Medicines is a biopharmaceutical company focused on developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets.
  • Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules, many of which are in late-stage clinical development.

Arcturus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, December 19, 2022
Health, Infectious Diseases, Genetics, General Health, Pharmaceutical, Biotechnology, OTC, Gene editing, Infection, Hepatitis B virus, Severe acute respiratory syndrome coronavirus 2, Webcast, RNA, Liver, Patent, RNA transfection, Wright Investors' Service Holdings, Inc., III, COVID-19, Messenger RNA, Conference, Annual, ARCT, DNA, Glycogen storage disease type III, Therapy, Vaccine, Cystic fibrosis

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will present at the Annual J.P. Morgan Healthcare Conference in San Francisco, on Wednesday, January 11, 2023, at 9:00 a.m. Pacific Time.

Key Points: 
  • Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will present at the Annual J.P. Morgan Healthcare Conference in San Francisco, on Wednesday, January 11, 2023, at 9:00 a.m. Pacific Time.
  • A webcast and replay of the presentation will be available on the “Investor Relations/Events” section of the Company’s website at: https://ir.arcturusrx.com/investor-calendar .
  • Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.
  • Arcturus’ technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries).

Fosun International Garners Multiple ESG Awards in Domestic and International Markets

Retrieved on: 
Friday, December 30, 2022
Benchmark, Sustainable Development Goals, Vaccination, Patient, CSR (company), United Nations, Morgan Stanley, Hang Seng China 50 Index, Environment, United Nations Global Compact, Fosun Pharma, Hang Seng Index, Goldman Sachs, RNA transfection, Omicron, COVID-19, ABC Family Worldwide, FTSE Russell, Conference, Face, Hang Seng Composite Index Series, MSCI, UN, Government, First Nations in Ontario, Consumer, BioNTech, Pfizer–BioNTech COVID-19 vaccine, ESG, Citigroup, Film, Vaccine, Pharmaceutical industry, Renewable energy, Lithium, Azvudine, Fosun International

HONG KONG, Dec. 29, 2022 /PRNewswire/ -- Recently, Fosun International received numerous accolades in domestic and international markets, including multiple ESG awards from international financial media International Business Magazine, Finance Derivative and Hong Kong stock connect information platform Zhitong Caijing.

Key Points: 
  • HONG KONG, Dec. 29, 2022 /PRNewswire/ -- Recently, Fosun International received numerous accolades in domestic and international markets, including multiple ESG awards from international financial media International Business Magazine, Finance Derivative and Hong Kong stock connect information platform Zhitong Caijing.
  • A number of investment banks, including Morgan Stanley, Citi, and Goldman Sachs, have published reports and assigned Fosun International an "Overweight" or "Buy" rating.
  • Since 2019, Fosun International has established the ESG Board Committee and the ESG Working Group to comprehensively improve ESG management and ensure the implementation of each ESG indicator.
  • Fosun International has also established an ESG Management Committee as well as an ESG Executive Committee to promote the effective implementation of ESG strategies and initiatives.

Clinical Genomics AI Commercial Use Cases Analyses Report 2022: Highlights of 14 Most Admired and Innovative Companies

Retrieved on: 
Thursday, December 29, 2022
DL, TEMPUS, Informatics, Siemens Healthineers, Whole genome sequencing, AI, RNA transfection, Diagnosis, Laika (EHR testing framework), Precision medicine, SWOT, Genomics, Sophia Genetics, Automation, DNAnexus, Therapy, Original equipment manufacturer, Algorithm, Deep learning, Research, Artificial intelligence, Machine learning, Hospital, University, Biomarker, Medical device, Antibiotics

DUBLIN, Dec. 29, 2022 /PRNewswire/ -- The "AI Commercial Use Cases, Impact Analyses, and Growth Opportunities in Clinical Genomics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Dec. 29, 2022 /PRNewswire/ -- The "AI Commercial Use Cases, Impact Analyses, and Growth Opportunities in Clinical Genomics" report has been added to ResearchAndMarkets.com's offering.
  • The study highlights fourteen 'Use Cases and Impact Analyses' of some of the most admired and innovative companies, such as Bionano Genomics, Inc, Deepcell, Inc., Fabric Genomics, Q-State Biosciences, Inc. TEMPUS, Sophia Genetics, Illumina, Qiagen, MolecularMatch, PierianDx, Inc., Dante Labs Inc., Microsoft Genomics, Intel Genomics, and Siemens Healthineers.
  • Clinical genomics regained significance during the pandemic with the development of the mRNA COVID-19 vaccine, and several non-invasive at-home test kits; an unprecedented feat in recent times.
  • Genomics will take center stage, as large genome sequencing and research will continuously create data for new therapeutics.

Cipla EU to Invest EUR 15 million in Ethris, initiating a strategic collaboration

Retrieved on: 
Thursday, December 29, 2022
BSE, Person-centered therapy, NSE, Patient, EUR, Writing, RNA, Development, Urology, Partnership, RNA transfection, Inhalation, Respiratory system, Gene, HIV, HIV/AIDS, Degenerative disease, Movement, Vaccine, Cardiology, Pharmaceutical industry, EU, Cipla

MUMBAI, India and MUNICH, Germany, Dec. 29, 2022 /PRNewswire/ -- Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) referred to as "Cipla" today announced that its wholly-owned UK subsidiary, Cipla (EU) Limited ("Cipla EU") has signed definitive agreements for equity investment of EUR 15 million in Ethris GmbH ("Ethris"), a global leader in delivering mRNAs directly to the respiratory system including administration by inhalation.

Key Points: 
  • MUMBAI, India and MUNICH, Germany, Dec. 29, 2022 /PRNewswire/ -- Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) referred to as "Cipla" today announced that its wholly-owned UK subsidiary, Cipla (EU) Limited ("Cipla EU") has signed definitive agreements for equity investment of EUR 15 million in Ethris GmbH ("Ethris"), a global leader in delivering mRNAs directly to the respiratory system including administration by inhalation.
  • A collaboration agreement is signed concurrently with the definitive agreement, which paves a path to market Ethris' innovative portfolio in Cipla's key emerging markets.
  • Umang Vohra, Managing Director & Global Chief Executive Officer of Cipla, said: "This collaboration accelerates our innovation journey and enables us to provide access to cutting-edge healthcare solutions to our patients.
  • We expect mRNA-based therapies to be one of the key innovation levers for Cipla.

Cipla EU to Invest EUR 15 million in Ethris, initiating a strategic collaboration

Retrieved on: 
Thursday, December 29, 2022
BSE, Person-centered therapy, NSE, IQVIA, Patient, EUR, Writing, RNA, Development, Urology, Partnership, RNA transfection, Inhalation, Respiratory system, Gene, HIV, HIV/AIDS, Degenerative disease, CNS, Movement, Vaccine, Cardiology, Pharmaceutical industry, EU, Cipla

MUMBAI, India and MUNICH, Germany, Dec. 29, 2022 /PRNewswire/ -- Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) referred to as "Cipla" today announced that its wholly-owned UK subsidiary, Cipla (EU) Limited ("Cipla EU") has signed definitive agreements for equity investment of EUR 15 million in Ethris GmbH ("Ethris"), a global leader in delivering mRNAs directly to the respiratory system including administration by inhalation.

Key Points: 
  • MUMBAI, India and MUNICH, Germany, Dec. 29, 2022 /PRNewswire/ -- Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) referred to as "Cipla" today announced that its wholly-owned UK subsidiary, Cipla (EU) Limited ("Cipla EU") has signed definitive agreements for equity investment of EUR 15 million in Ethris GmbH ("Ethris"), a global leader in delivering mRNAs directly to the respiratory system including administration by inhalation.
  • A collaboration agreement is signed concurrently with the definitive agreement, which paves a path to market Ethris' innovative portfolio in Cipla's key emerging markets.
  • Umang Vohra, Managing Director & Global Chief Executive Officer of Cipla, said: "This collaboration accelerates our innovation journey and enables us to provide access to cutting-edge healthcare solutions to our patients.
  • We expect mRNA-based therapies to be one of the key innovation levers for Cipla.

Fosun International Granted Three Awards from Global Banking and Finance Review in the United Kingdom

Retrieved on: 
Friday, December 23, 2022
Benchmark, Vaccination, Corporate social responsibility, Teaching hospital, Ernst & Young Entrepreneur of the Year Award, Hang Seng China 50 Index, Gunnerus Sustainability Award, Fosun Pharma, Infrastructure Development Company, CSR, RNA transfection, Hang Seng Index, Omicron, Social responsibility, Insurance, COVID-19, ABC Family Worldwide, Islam, FTSE Russell, Face, Hang Seng Composite Index Series, Global Banking & Finance Review, MSCI, United Kingdom, Government, BioNTech, Sustainable development, Pfizer–BioNTech COVID-19 vaccine, ESG, Vaccine, Lithium, Fosun International

HONG KONG, Dec. 22, 2022 /PRNewswire/ -- On 23 December 2022, Fosun International was notified by Global Banking and Finance Review, a famous financial magazine in the United Kingdom, that Fosun International was granted three awards, namely "Brand of the Year Awards - Holding Group Brand of the Year Awards Asia 2022", "ESG & Sustainability Awards - Best Sustainable Development Company Asia 2022" and "Corporate Social Responsibility (CSR) Awards - Best CSR Company Asia 2022", respectively.

Key Points: 
  • HONG KONG, Dec. 22, 2022 /PRNewswire/ -- On 23 December 2022, Fosun International was notified by Global Banking and Finance Review, a famous financial magazine in the United Kingdom, that Fosun International was granted three awards, namely "Brand of the Year Awards - Holding Group Brand of the Year Awards Asia 2022", "ESG & Sustainability Awards - Best Sustainable Development Company Asia 2022" and "Corporate Social Responsibility (CSR) Awards - Best CSR Company Asia 2022", respectively.
  • Fosun has been awarded by Global Banking and Finance Review in recognition of Fosun's active promotion in the sustainable development and ESG.
  • Global Banking and Finance Review Magazine is a leading magazine in the United Kingdom.
  • The Global Banking and Finance Review Awards were established in 2011 to accomplish companies with outstanding performances within the global finance industry.

CGTN: New Approaches : How China pushes COVID-19 vaccine R&D and inoculation

Retrieved on: 
Tuesday, December 20, 2022
Tao, COVID-19 vaccine, Vaccination, World Health Organization, Respiratory disease, Injection, WHO, Immune system, RNA transfection, COVID-19, NHC, Coronavirus, National Government, Epidemiology, Fortis Healthcare, Infection, Vaccine, National Health Commission, Ageing, Animal, Pharmaceutical industry, Aquaculture, Sinovac Biotech

It made substantial progress of vaccine development in five different technologies including inactivated vaccine, viral vector vaccine, recombinant protein vaccine, live attenuated influenza vaccine and nucleic acid vaccine.

Key Points: 
  • It made substantial progress of vaccine development in five different technologies including inactivated vaccine, viral vector vaccine, recombinant protein vaccine, live attenuated influenza vaccine and nucleic acid vaccine.
  • Three years into pandemic, China has approved 13 COVID-19 vaccines, including five inactivated vaccines, five recombinant protein vaccines, two viral vector vaccines and one live attenuated influenza vaccine.
  • China also has the most inoculation plans for its domestically developed COVID-19 vaccines that are based on inactivated virus, viral vector and recombinant protein.
  • China, with a population of 1.4 billion, has had administered nearly 3.46 billion doses of COVID-19 vaccines nationwide and provided over 2 billion doses worldwide.